These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1423 related articles for article (PubMed ID: 12867608)

  • 1. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
    N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.
    Yang L; Sun Y; Huang XE; Yu DS; Zhou JN; Zhou X; Li DZ; Guan X
    Asian Pac J Cancer Prev; 2015; 16(4):1545-51. PubMed ID: 25743829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Elsaleh H; Iacopetta B
    Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.
    Carethers JM; Smith EJ; Behling CA; Nguyen L; Tajima A; Doctolero RT; Cabrera BL; Goel A; Arnold CA; Miyai K; Boland CR
    Gastroenterology; 2004 Feb; 126(2):394-401. PubMed ID: 14762775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
    Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability.
    Johnson L; Chu E
    Clin Colorectal Cancer; 2002 Nov; 2(3):146-8. PubMed ID: 12482330
    [No Abstract]   [Full Text] [Related]  

  • 9. Microsatellite instability and colorectal cancer prognosis.
    Benatti P; Gafà R; Barana D; Marino M; Scarselli A; Pedroni M; Maestri I; Guerzoni L; Roncucci L; Menigatti M; Roncari B; Maffei S; Rossi G; Ponti G; Santini A; Losi L; Di Gregorio C; Oliani C; Ponz de Leon M; Lanza G
    Clin Cancer Res; 2005 Dec; 11(23):8332-40. PubMed ID: 16322293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
    Niv Y
    Isr Med Assoc J; 2005 Aug; 7(8):520-4. PubMed ID: 16106779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
    Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
    N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
    Collura A; Lagrange A; Svrcek M; Marisa L; Buhard O; Guilloux A; Wanherdrick K; Dorard C; Taieb A; Saget A; Loh M; Soong R; Zeps N; Platell C; Mews A; Iacopetta B; De Thonel A; Seigneuric R; Marcion G; Chapusot C; Lepage C; Bouvier AM; Gaub MP; Milano G; Selves J; Senet P; Delarue P; Arzouk H; Lacoste C; Coquelle A; Bengrine-Lefèvre L; Tournigand C; Lefèvre JH; Parc Y; Biard DS; Fléjou JF; Garrido C; Duval A
    Gastroenterology; 2014 Feb; 146(2):401-11.e1. PubMed ID: 24512910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability in colon cancer.
    Allegra CJ; Kim G; Kirsch IR
    N Engl J Med; 2003 Oct; 349(18):1774-6; author reply 1774-6. PubMed ID: 14585950
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
    Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H
    Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of microsatellite instability in the management of colorectal cancers.
    Buecher B; Cacheux W; Rouleau E; Dieumegard B; Mitry E; Lièvre A
    Dig Liver Dis; 2013 Jun; 45(6):441-9. PubMed ID: 23195666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
    Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
    Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
    Hamaya Y; Guarinos C; Tseng-Rogenski SS; Iwaizumi M; Das R; Jover R; Castells A; Llor X; Andreu M; Carethers JM
    PLoS One; 2015; 10(5):e0127591. PubMed ID: 25996601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
    Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
    Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.